Skip to main content

Table 2 Change in self-reported neurotoxicity scores (FACT/GOG-Ntx subscale) pre to post chemotherapy treatment by population characteristics (n = 900)

From: Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221)

 

Total

< 10%a

10–30%a

> 30%a

p valueb

Characteristic (mean ± SD)

 

281 (31.2)

306 (34.0)

313 (34.8)

 

Age at baseline (years) (52.0 ± 9.7)c

    

0.003

  < 40

93 (10.3)

33 (11.7)

43 (14.1)

17 (5.4)

 

 40–49

275 (30.6)

97 (34.5)

87 (28.5)

91 (29.1)

 

 50–59

323 (35.9)

92 (32.7)

109 (35.7)

122 (39.0)

 

  ≥ 60

208 (23.1)

59 (21.0)

66 (21.6)

83 (26.5)

 

Race/ethnicity

    

0.98

 Non-Hispanic White

762 (84.7)

238 (84.7)

259 (84.6)

265 (84.7)

 

 Spanish/Latino/Hispanic

27 (3.0)

7 (2.5)

9 (2.9)

11 (3.5)

 

 Black/African American

56 (6.2)

19 (6.8)

20 (6.5)

17 (5.4)

 

 Other

55 (6.1)

17 (6.1)

18 (5.9)

20 (6.4)

 

BMI at baseline (kg/m2)c (28.7 ± 6.5)

    

0.03

 Underweight (< 18.5)

8 (0.9)

6 (2.2)

1 (0.3)

1 (0.3)

 

 Normal/underweight (18.5–24.9)

278 (31.3)

103 (37.1)

103 (34.1)

72 (23.3)

 

 Overweight (25.0–29.9)

287 (32.3)

84 (30.22)

85 (28.2)

118 (38.2)

 

 Obese (30.0+)

316 (35.6)

85 (30.6)

113 (37.4)

118 (38.2)

 

BMI at follow-up (kg/m2)c (28.5 ± 6.4)

    

0.16

 Underweight (< 18.5)

8 (0.9)

4 (1.4)

2 (0.7)

2 (0.7)

 

 Normal (18.5–24.9)

281 (31.7)

103 (37.2)

99 (33.0)

79 (25.6)

 

 Overweight (25.0–29.9)

304 (34.3)

93 (33.6)

88 (29.3)

123 (39.8)

 

 Obese (30.0+)

293 (33.1)

77 (27.8)

111 (37.0)

105 (34.0)

 

Change in weight during treatment

    

0.007

 Lost weight

56 (6.2)

8 (2.9)

15 (4.9)

33 (10.5)

 

 Did not change

772 (85.8)

256 (91.1)

263 (86.0)

253 (80.8)

 

 Gained weight

72 (8.0)

17 (6.1)

28 (9.2)

27 (8.6)

 

Menopausal status

    

0.009

 Pre

407 (45.2)

135 (48.0)

152 (49.7)

120 (38.3)

 

 Post

493 (54.8)

146 (52.0)

154 (50.3)

193 (61.7)

 

Smoking status

    

0.09

 Never

511 (57.0)

169 (60.4)

182 (59.7)

160 (51.3)

 

 Former

285 (31.8)

84 (30.0)

94 (30.8)

107 (34.3)

 

 Current

101 (11.3)

27 (9.6)

29 (9.5)

45 (14.4)

 

Highest education

    

0.21

 Did not complete high school

51 (5.7)

22 (7.9)

11 (3.6)

18 (5.8)

 

 High school

188 (21.0)

54 (19.4)

63 (20.7)

71 (22.7)

 

 Some college or technical school

325 (36.3)

97 (34.8)

105 (34.5)

123 (39.3)

 

 College graduate

196 (21.9)

64 (22.9)

70 (23.0)

62 (19.8)

 

 Advanced degree

136 (15.2)

42 (15.1)

55 (18.1)

39 (12.5)

 

Marital status

    

0.80

 Married/living as married

682 (76.2)

216 (77.1)

232 (76.6)

234 (75.0)

 

 Widowed

38 (4.3)

15 (5.4)

9 (3.0)

14 (4.5)

 

 Divorced/separated

127 (14.2)

35 (12.5)

45 (14.9)

47 (15.1)

 

 Single/never married

48 (5.4)

14 (5.0)

17 (5.6)

17 (5.5)

 
  1. Data presented as N (%)
  2. SD standard deviation, FACT/GOG-Ntx Functional Assessment of Cancer Treatment Gynecologic Oncology Group—Neurotoxicity
  3. aPercent increase in neuropathy severity (based on self-reported score)
  4. bChi-square test for independence, analysis of variance for continuous variables (α = 0.05)
  5. cModeled as continuous variable
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us